Oxford BioMedica (OTCMKTS:OXBDF – Get Free Report) gapped down prior to trading on Tuesday . The stock had previously closed at $7.93, but opened at $7.34. Oxford BioMedica shares last traded at $7.34, with a volume of 100 shares traded.
Wall Street Analyst Weigh In
Separately, Zacks Research raised Oxford BioMedica to a “hold” rating in a research report on Wednesday, July 22nd. One research analyst has rated the stock with a Hold rating, According to data from MarketBeat, the company currently has a consensus rating of “Hold”.
Read Our Latest Report on OXBDF
Oxford BioMedica Stock Performance
Oxford BioMedica Company Profile
Oxford BioMedica is a clinical-stage gene and cell therapy company headquartered in Oxford, United Kingdom. The company specializes in the development, manufacturing and commercialization of lentiviral vector delivery systems for use in treating serious diseases. Its proprietary LentiVector® platform underpins both in-house development programs and third-party collaborations, enabling the stable integration of therapeutic genes into target cells.
In its research pipeline, Oxford BioMedica is advancing candidates across ophthalmology, neuroscience and oncology indications.
Recommended Stories
- Five stocks we like better than Oxford BioMedica
- System Upgrade: First Internet Bancorp Options Surge
- AI Security Breaches Raise New Risks for Microsoft and Amazon’s Agent Push
- The AI Chip Blockade Is Creating a Shadow Market
- Grab Holdings Stock Forms Bottom After Strong Beat-and-Raise Quarter
Receive News & Ratings for Oxford BioMedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford BioMedica and related companies with MarketBeat.com's FREE daily email newsletter.
